Get the Stockscreener App
7.05
1.29%
0.09
After Hours:
6.90
-0.15
-2.13%
Quantum Biopharma Ltd stock is traded at $7.05, with a volume of 27,685.
It is up +1.29% in the last 24 hours and down -18.50% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$6.96
Open:
$6.96
24h Volume:
27,685
Relative Volume:
0.25
Market Cap:
$27.09M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.73%
1M Performance:
-18.50%
6M Performance:
-37.22%
1Y Performance:
+325.98%
1-Day Range:
$6.87
$7.18
1-Week Range:
$6.85
$7.50
52-Week Range:
$1.445
$19.12
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
7.05 | 26.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
QNTM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Quantum Biopharma Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares - Newport Daily News
Aug Mood: Should I hold or sell Quantum BioPharma Ltd now - baoquankhu1.vn
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming DeadlinesQNTM - PR Newswire
Aug Outlook: Will Quantum BioPharma Ltd. outperform during market ralliesVolume Spike & Low Volatility Stock Recommendations - baoquankhu1.vn
CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM - Chartmill
Buyback Watch: Will Quantum BioPharma Ltd. stock attract ESG investors2025 Growth vs Value & Fast Entry and Exit Trade Plans - Bộ Nội Vụ
QNTM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Quantum Biopharma Ltd. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
QNTM DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026 - NewMediaWire
Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma - GlobeNewswire
Spoofing Allegations Against Banks Take Center Stage in Biotech’s Legal Fight - InvestorNews
User - FinancialContent
About Us - FinancialContent
QUANTUM BIOPHARMA DEADLINE FOR LEADERSHIP is February 23, 2026 in - The National Law Review
Quantum BioPharma closes private placement, enhances governance - MSN
QUANTUM BIOPHARMA DEADLINE FOR LEADERSHIP is February 23, 2026 in a Securities Fraud LawsuitContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
Daily Breeze - FinancialContent
Quantum BioPharma Heads For Best Week Ever — But Most Retail Traders Lament Missing Out On The Surge - MSN
Deadline to Lead in Securities Class Action Against Quantum Biopharma Ltd. (QNTM) is February 23, 2026Contact Kaplan Fox - NewMediaWire
Star Tribune - FinancialContent
QNTM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Quantum Biopharma Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Whittier Daily News - FinancialContent
How supply chain issues affect Quantum BioPharma Ltd. stockJuly 2025 Big Picture & AI Forecasted Stock Moves - Улправда
Will Quantum BioPharma Ltd. stock attract ESG investorsJuly 2025 Momentum & Stepwise Trade Signal Guides - Улправда
How strong is Quantum BioPharma Ltd. stock balance sheetTreasury Yields & Real-Time Volume Trigger Notifications - Улправда
Will Quantum BioPharma Ltd. (0K91) stock enhance shareholder value2025 Price Momentum & Free Expert Verified Stock Movement Alerts - Улправда
QNTM CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026 - NewMediaWire
Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026 - FinancialContent
QNTM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Quantum Biopharma Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Why Quantum BioPharma Ltd. (0K91) stock signals breakout potentialTreasury Yields & Consistent Growth Stock Picks - Улправда
How Quantum BioPharma Ltd. stock reacts to global recession fearsRetail Trading Trends & Budget Friendly Trading Ideas - Улправда
Is Quantum BioPharma Ltd. (0K91) stock dividend growth reliableStock Watchlist Updates & Big Returns Small Capital - ulpravda.ru
QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026 - NewMediaWire
Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026 - FinancialContent
Kaplan Fox Alerts Quantum Biopharma Ltd. (QNTM) Investors to a Se - The National Law Review
QNTM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Quantum Biopharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
QNTM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Quantum Biopharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
QNTM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Quantum Biopharma Ltd. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
QUANTUM BIOPHARMA Investors are Encouraged to Contact Kaplan Fox Regarding the Securities Class Action Lawsuit - NewMediaWire
StreetInsider.comQUANTUM BIOPHARMA Investors are Encouraged to Contact Kaplan Fox Regarding the Securities Class Action Lawsuit - FinancialContent
Kaplan Fox Reminds Quantum Biopharma Ltd. (QNTM) Investors of a Securities Class Action Lawsuit - The Globe and Mail
Kaplan Fox Encourages Investors of Quantum Biopharma Ltd. (QNTM) to Contact the Firm Regarding the Securities Class Action Lawsuit - NewMediaWire
QNTM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Quantum Biopharma Ltd. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Kaplan Fox Alerts Investors of Quantum Biopharma Ltd. (QNTM) to a Securities Class Action Lawsuit - The National Law Review
QNTM STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Quantum Biopharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Kaplan Fox Alerts Investors to Securities Class Action on Behalf of Quantum Biopharma Ltd. (QNTM) Shareholders - NewMediaWire
Cannabis Stocks To Follow TodayDecember 11th - MarketBeat
Quantum Biopharma Ltd Stock (QNTM) Financials Data
There is no financial data for Quantum Biopharma Ltd (QNTM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):